EMMLF - EMMLF STOCK NEWS

OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, acquired 200,000 ordinary shares at prices ranging from 5p to 5.5p each. This purchase increased Mr. Cerrone's beneficial ownership from 52.64% to 52.66%. The transaction occurred on January 26, 2022, with shares traded on the London Stock Exchange.

OKYO Pharma Limited reported interim results for the six months ending September 30, 2021. Total assets decreased to £4.2 million, with cash on hand at £3.8 million. The total comprehensive loss was £1.8 million, up from £0.5 million in the prior year. The company focuses on developing drugs for inflammatory dry eye diseases and ocular pain, primarily targeting the GPCR family. OK-101, their lead candidate, is being prepared for an IND application with the FDA for treating dry eye disease, while development of OK-201 has been halted to concentrate on OK-101.

OKYO Pharma Limited (OTCQB: EMMLF) announced the issuance of a pivotal patent for its lead compound, OK-101, aimed at treating dry eye disease (DED). The U.S. Patent No. 11,197,906 encompasses methods to lower blink reflex associated with DED. OK-101, leveraging novel membrane-anchored-peptide technology, is expected to start Phase 2 clinical trials in Q4 2022 after an IND filing in Q3 2022. CEO Dr. Gary S. Jacob expressed optimism about the drug's potential to address unmet medical needs in DED treatment.

OKYO Pharma Limited (OTCQB: EMMLF) announced promising findings for its drug candidate OK-101, which effectively treats both dry eye disease (DED) and ocular pain. Developed under Dr. Pedram Hamrah at Tufts Medical Center, OK-101 showed significant pain relief in a mouse model, comparable to gabapentin, a standard pain medication. The drug's dual action addresses a critical unmet need, as DED patients frequently experience ocular pain. OKYO plans to file an IND for OK-101 in Q3 2022 and initiate a Phase 2 trial in Q4 2022, emphasizing the drug's potential to transform DED treatment.

OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) announced plans to file an IND for its lead compound, OK-101, aimed at treating dry eye disease (DED), with submission expected in Q3 2022. The Phase 2 clinical trial is set to begin in Q4 2022, involving 100 to 200 patients, aiming to evaluate the drug's efficacy. OK-101 utilizes a novel mechanism targeting ChemR23 receptors, demonstrating promising anti-inflammatory properties in pre-clinical models. OKYO aims to expedite the drug's development process, bypassing typical Phase 1 trials for non-life-threatening conditions.

OKYO Pharma Limited has appointed Bernard Denoyer as a non-executive director. Denoyer brings 49 years of financial management experience, including key roles at Synergy Pharmaceuticals and Callisto Pharmaceuticals. He has supported over $500 million in public and PIPE financings and possesses a strong educational background, with degrees from Columbia and Fairfield universities. His expertise will be valuable during a crucial time for OKYO, focusing on novel treatments for inflammatory dry eye diseases and chronic pain.

OKYO (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on developing novel treatments for inflammatory dry eye diseases and chronic pain, announced that all resolutions were successfully passed at its Annual General Meeting held on September 27, 2021. The details of the proxy voting results will be published on the Company's website. OKYO Pharma is listed on the Official List of the UK Financial Conduct Authority and trades on the main market of the London Stock Exchange.

OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) has announced its annual general meeting (AGM) scheduled for September 27, 2021, at 10:00 a.m. The notice and proxy form for the AGM will be sent to shareholders and made available on the company's website. This year, the meeting will be conducted virtually, allowing shareholders to attend and participate in the voting process. All voting will occur on a poll basis, and shareholders are encouraged to submit questions in advance. Full AGM details can be found in the Notice of AGM.

OKYO Pharma Limited announced its audited financial results for the year ending March 31, 2021. The company experienced a total comprehensive loss of £2.994 million, an increase from £1.211 million in 2020. Cash reserves increased significantly to £4.991 million due to successful fundraising efforts totaling £6.070 million. OKYO-101, a promising candidate for treating dry eye disease, showed positive results in animal models, and the company plans to file an IND in Q3 2022. The pipeline also includes OK-201 for neuropathic pain and ongoing research for COVID-19 related treatments.